Therapeutic potential of compounds targeting SARS-CoV-2 helicase

The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase s...

Descripción completa

Detalles Bibliográficos
Autores principales: Halma, Matthew T. J., Wever, Mark J. A., Abeln, Sanne, Roche, Didier, Wuite, Gijs J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763700/
https://www.ncbi.nlm.nih.gov/pubmed/36561139
http://dx.doi.org/10.3389/fchem.2022.1062352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763700/
https://www.ncbi.nlm.nih.gov/pubmed/36561139
http://dx.doi.org/10.3389/fchem.2022.1062352

Ejemplares similares